Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Aclaris Therapeutics, Inc. (ACRS)

Pharmaceutical Preparations

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

701 LEE ROAD, SUITE 103
WAYNE, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/07/2015

Market Cap

85,256,797

Shares Outstanding

70,840,000

Weighted SO

70,836,194

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

NEOG --.--%

QGEN --.--%

OLK --.--%

SYNH --.--%

SHC --.--%

RDNT --.--%

MYGN --.--%

GTH --.--%

BDSX --.--%

Beta

0.2820

Last Div

0.0000

Range

0.59-8.275

Chg

0.0150

Avg Vol

878835

Mkt Cap

85256797

Exch

NASDAQ

Country

US

Phone

484 324 7933

DCF Diff

1.3290

DCF

-0.0690

Div Yield

0.0000

P/S

2.6629

EV Multiple

-0.6493

P/FV

0.6366

Div Yield %

0.0000

P/E

-1.4519

PEG

-0.0357

Payout

0.0000

Current Ratio

7.5013

Quick Ratio

7.5013

Cash Ratio

1.4561

DSO

3.7052

DIO

0.0000

Op Cycle

3.7052

DPO

240.6517

CCC

-236.9465

Gross Margin

0.6556

Op Margin

-1.9306

Pretax Margin

-1.8443

Net Margin

-1.8328

Eff Tax Rate

0.0065

ROA

-0.3643

ROE

-0.3983

ROCE

-0.4251

NI/EBT

0.9938

EBT/EBIT

0.9553

EBIT/Rev

-1.9306

Debt Ratio

0.0028

D/E

0.0034

LT Debt/Cap

0.0000

Total Debt/Cap

0.0033

Int Coverage

-38.6306

CF/Debt

-143.5523

Equity Multi

1.2036

Rec Turnover

98.5108

Pay Turnover

1.5167

Inv Turnover

0.0000

FA Turnover

7.2830

Asset Turnover

0.1988

OCF/Share

-0.9041

FCF/Share

-0.9132

Cash/Share

1.5583

OCF/Sales

-2.0132

FCF/OCF

1.0100

CF Coverage

-143.5523

ST Coverage

-143.5523

CapEx Coverage

-99.7755

Div&CapEx Cov

-99.7755

P/BV

0.6366

P/B

0.6366

P/S

2.6629

P/E

-1.4519

P/FCF

-1.3096

P/OCF

-1.3217

P/CF

-1.3217

PEG

-0.0357

P/S

2.6629

EV Multiple

-0.6493

P/FV

0.6366

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 22, 14:37 Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades Benzinga Jan 22, 14:37 Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades Benzinga Jan 10, 15:12 Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations Benzinga Dec 18, 10:39 Aclaris Therapeutics Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week PennyStocks Dec 05, 17:10 Penny Stocks To Buy Now? 5 Under $5 To Watch This Week

Revenue Product Segmentation